Fight against COVID-19
Diagnostic antibody & antigen
Services
- Custom AAV Production
- Custom Adenovirus Production
- Custom Lentivirus Production
- Pre-made AAV Production
- Pre-made Adenovirus Production
- Pre-made Lentivirus Production
- AAV-LC3 Autophagy Flux Detection
- Ad-LC3 Autophagy Flux Detection
- Lv-LC3 Autophagy Flux Detection
- AAV Control Virus Production
- CRISPR/Cas9 AAV Production
- CRISPR/Cas9 Adenovirus Production
Supports
SOCAIL MEDIA
Recombinant 2019-nCoV(SARS-CoV-2) Spike Protein RBD (L452R+T478K) mutant (delta variant B.1.617.2 lineage
Cat No.: GMP-V-2019nCoV-Smu-023
Order information
| Package | Catalog No. | Price(In USD) | Qty (Quantity) | Sum(In USD) |
|---|---|---|---|---|
| 1mg | GMP-V-2019nCoV-Smu-023-1mg | 5990 | ||
| 10mg | GMP-V-2019nCoV-Smu-023-10mg | 38790 | ||
| 100mg | GMP-V-2019nCoV-Smu-023-100mg | 258000 | ||
| ≥100mg | GMP-V-2019nCoV-Smu-023-xmg | Inquiry | ||
| Shipping Cost: | 760.00 | |||
| Total: | ||||
Description
| Accession Number | QHD43415.1 |
| Expression platform | 2019-nCoV(SARS-CoV-2, SARS2-coronavirus) |
| Isotypes | Mamamlian (human cell) |
| Tag | C-His |
| Products description | Recombinant 2019-nCoV(SARS-CoV-2) Spike Protein RBD L452R mutant (double mutant variant B.1.617 lineage, S:E484Q+L452R (India)) was expressed in mammanlian cell (human cells) expression system with 6 HIS tag at the C-terminus. |
| Bioactivity validation | ACE2 binding; Immunogen in Sandwich Elisa, lateral-flow tests,and other immunoassays; |
| Purity | Purity: ≥95% (SDS-PAGE) |
| Application | Spike protein & ACE2 competition binding assay for efficacy evaluation of COVID-19 vaccines and therapeutic antibodies. Immunogen in Elisa,lateral-flow tests,and other immunoassays; Standard substance The antigen can also be used in drug discovery including antibody screening and lead compound candidates assay. |
| predicted Molecular Mass | 26kDa |
| Formulation | Lyophilized from sterile PBS, PH 7.4 |
| Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Recombinant 2019-nCoV(SARS-CoV-2) Spike Protein RBD L452R mutant (double mutant variant B.1.617 lineage, S:E484Q+L452R (India))
The world is in midst of the COVID-19 pandemic. Recently A new "double mutant" variant of the coronavirus has been detected from samples collected in India. The two mutations (E484Q and L452R mutations) come together in the same virus, may be more infectious or less affected by vaccines.1Mutations of Spike protein in SARS-COV-2 (2019nCOV) double mutant variant B.1.617 lineage, S:E484Q+L452R (India)
Two of the spike mutations are at key residues in the RBD (E484Q and L452R), two are in the N-terminal domain (T95I and E154K).
| Spike Mutation in SARS-COV-2 (2019nCOV) double mutant variant B.1.617 lineage, S:E484Q+L452R (India) | Spike-S1 Subunit N Terminal |
T95I | |
| E154K | Important residues mutation | ||
| Spike-RBD | L452R | Important residues mutation | |
| E484Q | Important residues mutation | ||
| Spike-S1 Subunit | D614G | A popular mutation in different new SARS-CoV-2 lineage | |
| Spike-S2 Subunit | P681R |
Figure. Amino acid changes in the spike region of the double mutant variant B.1.617 lineage, S:E484Q+L452R (India) genomes2
